跳转至内容
Merck
所有图片(1)

Key Documents

H1428000

羟钴胺

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C62H89CoN13O15P
CAS号:
分子量:
1346.36
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

hydroxocobalamin

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

運輸包裝

wet ice

儲存溫度

−20°C

InChI

1S/C62H89N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H2,63,77)(H2,64,78)(H2,65,79)(H2,66,80)(H2,67,81)(H2,68,82)(H,69,83)(H,85,86);;1H2/q-2;+2;-1/p-1/t31-,34+,35+,36+,37-,41+,52+,53+,56?,57-,59+,60-,61-,62-;;/m0../s1

InChI 密鑰

PJOHJFIDLYDPIZ-PMEYKKDOSA-M

一般說明

本品按现行药典规定交付。该产品的所有支持信息,包括SDS和任何产品信息宣传页均由药典发行机构制定并发布。如需更多信息和支持,请见现行药典的网站。

應用

羟钴胺EP参考标准品的预期用途是欧洲药典规定的实验室测试。

包裝

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他說明

可能适用相应的销售限制。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Emilie Cornec-Le Gall et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 63(1), 119-123 (2013-11-12)
A 20-year-old man was hospitalized for malignant hypertension, mechanical hemolysis, and kidney failure. Kidney biopsy confirmed glomerular and arteriolar thrombotic microangiopathy. Etiologic analyses, which included ADAMTS13 activity, stool culture, complement factor proteins (C3, C4, factor H, factor I, and MCP
Hydroxocobalamin hinders hemodialysis.
Samuel J Stellpflug et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 62(2), 395-395 (2013-06-19)
Zhuo Huang et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics, 51(3), 194-198 (2013-06-12)
Combined methylmalonic acidemia with homocystinuria is a common form of methylmalonic acidemia in China. Patients with this disease can progress to death without timely and effective treatment. This study aimed to analyze the treatment outcomes of patients with combined methylmalonic
A man with tingling fingers.
Neal Larkman et al.
BMJ (Clinical research ed.), 346, f1443-f1443 (2013-03-20)
I Vaz Matos et al.
Molecular genetics and metabolism, 109(4), 360-365 (2013-06-12)
CblC deficiency produces a combination of methylmalonic aciduria (MMA) and homocystinuria (HCU), and is the most common error of cobalamin metabolism. Patients present a wide spectrum of symptoms, ranging from early severe multisystemic forms, to milder late-onset phenotypes. Cognitive and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门